STAT Plus: Congress is hoping for another major medical research bill. But pharma’s not nearly as excited as before
WASHINGTON — The bipartisan duo behind a 2016 law that poured billions into medical research…
Category: STAT Plus
.jpg)
STAT Plus: Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s
Does the Alzheimer’s drug aducanumab work? That was the central issue during an interview of…
STAT Plus: Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast
Good morning, everyone, an welcome to another working week. We hope the weekend respite, which…
STAT Plus: This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too
Steve Woit runs an exclusive, confidential, invite-only club for biotech CEOs — but it’s not…
STAT Plus: Startup Spotlight: Juno, Vir alum starts a new immunotherapy company
A Juno Therapeutics and Vir Biotechnology founder may be about to launch a new company…
STAT Plus: Biogen will offer discounts to a health plan if patients say its multiple sclerosis drugs don’t work
In a twist on value-based contracting, a drug maker has agreed to offer a larger…
STAT Plus: Pharmalittle: Feds probe drug makers for flooding communities with opioids; States proceeding with importation
And so, another working week will soon come to an end, but earlier than usual,…
STAT Plus: Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?
Unlike most biotech startups, Enlight Biosciences was never expected to make any drugs. Instead, the…
STAT Plus: EMA adopts EU Ombudsman recommendations to avoid bias concerns over drug approvals
Seeking to end another flap about transparency, the European Medicines Agency has agreed to recommendations…
STAT Plus: Pharmalittle: Generic makers talk to feds about ending price-fixing probe; how the Arnolds fueled the pricing debate in D.C.
Hello, everyone, and how are you today? We are doing just fine, thank you, now…
STAT Plus: Pharma execs tell researchers that multiple sclerosis drug pricing is based on competition, not R&D costs
Despite claims that prices for new medicines are generally shaped by R&D costs, initial pricing…
STAT Plus: Merck is probed by Spain’s antitrust regulator for allegedly delaying competition for a contraceptive
The antitrust regulator in Spain has accused Merck (MRK) of working with other companies to…
STAT Plus: Pharmalittle: Novartis to pay $9.7 billion for The Medicines Co.; Trump bashes Pelosi drug pricing bill
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own
A group of leading Boston-area universities, hospitals, and corporations will create a new center for…
STAT Plus: Watch: The state of biotech at time of innovation — and high prices
CAMBRIDGE, Mass. — We live in an age of miracles, but they come at a…
STAT Plus: A bold prediction: Machine learning will yield new drug candidates within three years
CAMBRIDGE, Mass. — An explosion of biological data will lead to the first drug candidates…
STAT Plus: ‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation
CAMBRIDGE, Mass. — Biopharma’s reputation is, objectively speaking, the worst. And on Thursday, several biotech…
STAT Plus: Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’
CAMBRIDGE, Mass. — Gene therapy pioneer Dr. James Wilson is disappointed by the progress in…
STAT Plus: Pharmalittle: Trump and senators push for drug prices in TV ads; Sanofi looks to spin off consumer business
Top of the morning to you, and a fine one it is. We may have…
STAT Plus: Patient charity settles allegations it helped MS drug makers pay kickbacks
A patient assistance charity has agreed to pay $4 million to settle allegations that it…
STAT Plus: Pharmalittle: Purdue affiliate in China pushes misleading opioid claims; more generics are approved but not yet available
Hello, everyone, and nice to see you again after a brief sojourn in a foreign…
STAT Plus: Biotech venture capitalists form a lobbying coalition to join the drug pricing debate
A shorter version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about…
STAT Plus: Pharmalittle: How Purdue planted its ‘anti-story’; how much does that ‘free’ flu shot cost?
Good morning. Elizabeth Cooney here again in Boston while Ed Silverman completes another engagement abroad….
STAT Plus: Novo Nordisk’s parent company to launch research incubator in Boston
Novo Holdings, the investment firm behind pharmaceutical giant Novo Nordisk, is committing $25 million over…